In the case of the lung cancer drug ramucirumab, for example, the FDA cautions that patients treated with this drug must be those with epidermal growth factor receptor (EGFR) and ALK receptor tyrosine kinase (ALK) mutations [16,17]. This evidence concerns the gene EGFR and lung carcinoma.